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Abstract
Common variable immunodeficiency (CVID) is the most fre-
quent form of immunodeficiency in adults. Clinical manifes-
tations are heterogeneous with an increased susceptibility 
to infections and inflammatory conditions, namely autoim-
mune diseases, such as inflammatory bowel disease. We 
present the clinical case of a Caucasian female patient, 21 
years old, with a past medical history of CVID, with multiple 
visits to the emergency department due to abdominal pain 
in the lower quadrants and diarrhea. Her biochemical analy-
sis showed elevated inflammatory parameters. Stool cul-
tures and parasitological examination of feces were nega-
tive. Ileocolonoscopy revealed lymphoid nodular hyperpla-
sia of the terminal ileum, and the small bowel capsule 
endoscopy demonstrated edema and multiple pleomorphic 
ulcers (Lewis score = 1,104). CVID-associated inflammatory 
enteropathy was suspected. Budesonide 9 mg/day was 
started, but no positive clinical response was observed. It 
was decided to initiate biological therapy with infliximab. 
The patient’s condition is currently clinically improved with 
no complications due to biological therapy.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
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Resumo
A imunodeficiência variável comum (IDVC) é a forma mais 
frequente de imunodeficiência no adulto. O conjunto de 
manifestações clínicas é heterogéneo com uma susceti-
bilidade aumentada a infeções e condições inflamatórias, 
nomeadamente autoimunes como a doença inflamatória 
intestinal. Apresenta-se um caso clínico de doente do 
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sexo feminino, 21 anos de idade com antecedentes de 
imunodeficiência variável comum, com múltiplas admis-
sões ao serviço de urgência por dor abdominal nos 
quadrantes inferiores e diarreia. Analiticamente apresen-
tava parâmetros inflamatórios elevados. As coproculturas 
e exame parasitológico de fezes eram negativos. A ileoco-
lonoscopia revelou hiperplasia nodular linfóide do íleon 
terminal e a enteroscopia por cápsula edema marcado e 
múltiplas úlceras pleomórficas (Score de Lewis 1104). Sus-
peitou-se de enteropatia inflamatória associada a IDVC. 
Iniciou Budesonido 9 mg/dia não tendo sido verificada 
resposta clínica positiva. Foi decidido iniciar terapêutica 
biológica com Infliximab. A doente encontra-se, atual-
mente, clinicamente melhorada sem evidência de ativi-
dade inflamatória.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Since the first report over 60 years ago, common vari-
able immunodeficiency (CVID) appears to be the most fre-
quent form of primary immunodeficiency in adults and 
occurs equally in males and females [1, 2]. It generally pre-
sents in the second or third decades, although it may occur 
at any age [2]. It is a rare condition with an estimated prev-
alence that ranges from 1/100,000 to 1/10,000 of the popu-
lation [2]. Although the etiology is unknown [2], genetic 
factors are involved and seem to be responsible for the pre-
sentation and progression of the disease [1]. The diagnosis 
results from the combination of primary antibody IgG de-
ficiency, along with IgA and/or IgM deficiency, associated 
with reduced or absent antibody response against vaccina-
tion [1, 3]. The clinical spectrum is heterogeneous, and pa-
tients usually present a higher susceptibility to recurrent 
bacterial infection, namely sinopulmonary infections, au-
toimmune manifestations, and malignancy [4].
There is a higher incidence of autoimmune patholo-
gies in these patients, and, recently, emerging cases of in-
flammatory bowel disease have been described in the lit-
erature with a reported incidence of 2–4% [5]. We report 
a case of CVID-associated inflammatory enteropathy 
treated with infliximab with successful outcome.
Case Report
A 21-year-old female was referred to our Gastroenterology De-
partment after multiple admissions to the emergency room due to 
intense lower abdominal pain and chronic diarrhea with more 
Fig. 1. Abdominal computed tomography in the emergency room: ileal thickening was observed (arrows).
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than 6 months of evolution. She had a past medical history of 
CVID with multiple rhinopulmonary infections. She also had a 
history of pulmonary tuberculosis in 2005, which was successfully 
treated. She was on no regular medication and denied taking non-
steroidal anti-inflammatory drugs. She had no known allergies and 
had no family history of gastrointestinal pathology.
At the first admission to the emergency room, she had leuko-
cytosis and high C-reactive protein (CRP). At the same admission, 
an abdominal computed tomography was performed which re-
vealed ileal thickening (Fig. 1). To exclude small intestinal bacte-
rial overgrowth, she underwent a cycle of rifaximin 1,600 mg/day 
during 7 days, without positive clinical response.
At our observation, she presented with lower abdominal ten-
derness on physical exam. Extended laboratory data were accessed: 
hemoglobin 13.1 g/dL (normal: 12–16 g/dL); white blood cell 
count 10,100/μL (normal: 4.8–10.8 × 103/μL); platelet count 234 × 
103/μL (normal: 150–350 × 103/μL); erythrocyte sedimentation 
rate 18 mm (normal: 0–12 mm); CRP 71.6 mg/L (normal: < 3 
mg/L); albumin 3.5 g/dL (normal: 3.4–5 g/dL); folate 11 ng/mL 
(normal: 3.1–17.5 ng/mL); vitamin B12 282 pg/mL (normal: 211–
911 pg/mL); fecal calprotectin > 1,800 g/g (normal: < 50 g/g); IgM 
46.7 mg/dL (normal: 29–226 mg/dL); IgA < 7.8 mg/dL (normal: 
114–457 mg/dL); and IgG 255 mg/dL (normal: 793–1,590 mg/dL). 
Stool cultures and parasitological examination (3 specimens from 
3 different days), namely Giardia lamblia, were negative. 
IgG antitransglutaminase antibody was negative. Upper endos-
copy was normal, and biopsies of the bulb and second portion of 
the duodenum were performed, ruling out celiac disease. A colo-
noscopy with ileoscopy was executed. No lesions were observed in 
the colon, but the terminal ileum presented with edema and a nod-
ular appearance compatible with nodular lymphoid hyperplasia. 
Histopathological examination of the terminal ileum confirmed 
the diagnosis of nodular lymphoid hyperplasia. A small bowel cap-
sule endoscopy (SBCE) was also performed and showed edema 
and multiple pleomorphic ulcers on the third tertile with a Lewis 
score of 1,104 (severe inflammatory activity) (Fig. 2) [6, 7]. We 
concluded that all these findings taken together were consistent 
with CVID-associated inflammatory enteropathy. 
She was started on budesonide 9 mg/day, but abdominal pain 
and diarrhea persisted. After exclusion of active or latent tubercu-
losis, it was decided to initiate biological therapy with infliximab 
5 mg/kg at 0, 2, and 6 weeks (induction) and, after that, every 
8 weeks. After 14 weeks of infliximab, the patient showed clinical 
improvement and normalization of the acute phase reactants 
(erythrocyte sedimentation rate 3 mm and CRP < 2.9 mg/L) and 
fecal calprotectin (< 50 μg/g). A SBCE was performed 12 months 
after the onset of biological therapy to assess mucosal healing, 
which revealed nodular lymphoid hyperplasia with no ulcers or 
evidence of inflammatory activity (Fig. 3). No adverse effects, such 
as infections, were observed during the follow-up.
Discussion
Gastrointestinal manifestations in CVID are common, 
ranging from 20 to 60%. Up to 50% of patients have in-
termittent or chronic diarrhea, and 10% suffer from 
weight loss and malabsorption [8]. In the last years, the 
Fig. 2. Small bowel capsule endoscopy previ-
ous to biological treatment: edema and mul-
tiple pleomorphic ulcers were observed in 
the third tertile. 
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incidence of CVID-associated inflammatory enteropathy 
has ranged from 2 to 4% [5]. This clinical variability seems 
to be related to a complex pathogenesis with multiple 
mechanisms, suggesting a T-cell receptor-mediated path-
way dysregulation with an imbalance of proinflammatory 
cytokines [9]. In a subgroup of patients, a persistent acti-
vation of TNF-α may contribute to the pathogenesis of 
CVID-associated inflammatory enteropathy [9]. Besides, 
recent data suggest that deficiencies of JAK1 and JAK3 
are linked to combined immunodeficiency [10, 11]. In 
these patients, endoscopic appearance is not specific and 
is indistinguishable from inflammatory bowel disease pa-
tients without CVID [12]. Histological lesions of CVID-
associated inflammatory enteropathy show an absence of 
plasma cells in the lamina propria, lymphocytosis, apo-
ptosis, granulomas, and crypt distortion [13].
SBCE played an important role in the diagnosis of this 
patient, proving the need, in gastrointestinal symptom-
atic patients with a history of CVID and normal endos-
copy, to follow investigation, even though 50% of patients 
have chronic intermittent diarrhea. SBCE may also rule 
out complications of the disease and may establish small 
bowel extent.
There is no gold standard for therapeutic management 
of CVID-associated inflammatory enteropathy. Immu-
noglobulin replacement therapy, steroids, and immuno-
suppressive agents have been used, but their efficacy and 
tolerability are not well established [2, 13].
The first report in the literature was published in 2006 
by Nos et al. [14], reporting on 2 young patients who were 
diagnosed with CVID-associated inflammatory enteropa-
thy and were treated successfully with infliximab with no 
complications. Since then, some reports have been emerg-
ing, and anti-TNF-α drugs (infliximab and adalimumab) 
seem to be proper and powerful therapeutics in this type of 
patients with rapid control of severe symptoms [5, 15, 16].
In the current case, infliximab allowed clinical and lab-
oratory remission and mucosal healing without increased 
bacterial infections. Despite limited experience with bio-
logical therapy in CVID-associated inflammatory enter-
opathy, emerging case reports have shown remarkable 
clinical and analytical improvement in these patients, 
supporting biological drugs as a first-line therapy [5, 15–
17].
We would like to emphasize that SBCE has revolution-
ized the diagnosis and monitoring of Crohn disease, be-
ing a patient-friendly and noninvasive tool with proved 
advantages in diagnostic yield when compared to cross-
sectional imaging [18–20]. It allows a direct and detailed 
evaluation of small bowel mucosa with a high sensitivity 
for the earliest lesions, i.e., superficial lesions [18–20]. Re-
garding this case report, SBCE played a fundamental role 
in the diagnosis and in the monitoring of therapeutic re-
sponse in this rare entity.
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Fig. 3. Small bowel capsule endoscopy 12 months after infliximab: nodular lymphoid hyperplasia was observed 
in the third tertile, with no evidence of inflammatory activity.
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